Talus Bio
Talus Bio builds AI models that design drugs for proteins with no fixed 3D structure, trained on proprietary data measured inside living human cells.
Challenge
How do you launch a novel but technically complex AI drug discovery model into a field built around protein structure, and make that structure-free approach clear and credible to scientists, investors, and media?
Approach
Talus Bio partnered with Thermal to bring Talus’ first model, Ptarmigan-1 from preprint to public launch. Together, we:
-
- Sharpened positioning: Framed Ptarmigan-1 as a fundamentally different tool for a class of proteins not touched by traditional models, pressure-testing every claim around what the model offered.
- Prepared founders for the spotlight: Ran media prep sessions and mock interviews with leadership and built a story bank of founder anecdotes, from Alex Federation’s grad school origins to the mountain-terrain roots of the Talus and Ptarmigan names.
- Built a launch-day media sequence: Secured an in-depth trade exclusive, timed the wire release behind it, then pitched reporters across trade and science media.
- Developed a social media plan: Audited Talus Bio’s social presence, identified founder and employee feeds as the strongest channels, and coordinated corporate and leadership post sequencing to maximize launch day impact.
- Positioned the founders and company for recognition: Started an awards and thought-leadership program.
Impact
Together, we:
-
- Secured a deep-dive trade exclusive: Genetic Engineering and Biotechnology News published a thorough feature on Ptarmigan-1 that carried the founder story alongside the science behind Ptarmigan-1.
- Procured additional media attention through strategic awards: Secured stories in additional trade publications and newsletters, including Drug Discovery News and PharmaVoice, to amplify attention around the model launch.
- Opened doors with tier-one science media: Created a pipeline for follow-on stories, with interest from multiple reporters asking to meet the co-founders.
- Owned the “structure-free” narrative: Coverage framed Ptarmigan-1 around its 5,000x speed gain and its reach into proteins that folding models can’t target.
“With Ptarmigan-1, we now have a complementary approach for roughly half of all human proteins that have evaded drug discovery because they can’t be folded in a computer.”
Alexander Federation – CEO of Talus Bio

